

BIOMARIN PHARMACEUTICAL INC  
 Form 4  
 September 18, 2007

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL  
 OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BAFFI ROBERT**

(Last) (First) (Middle)

C/O BIOMARIN  
 PHARMACEUTICAL INC., 105  
 DIGITAL DRIVE

(Street)

NOVATO, CA 94949

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**BIOMARIN PHARMACEUTICAL INC [BMRN]**

3. Date of Earliest Transaction  
 (Month/Day/Year)  
**09/14/2007**

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 SVP, Technical Operations

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock	09/14/2007		M	90,000	A \$ 6.13	123,124	D
Common Stock	09/14/2007		S	300	D \$ 22.34	122,824	D
Common Stock	09/14/2007		S	2,800	D \$ 22.35	120,024	D
Common Stock	09/14/2007		S	1,150	D \$ 22.36	118,874	D
	09/14/2007		S	2,550	D \$ 22.37	116,324	D

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock							
Common Stock	09/14/2007	S	4,450	D	\$ 22.38	111,874	D
Common Stock	09/14/2007	S	500	D	\$ 22.39	111,374	D
Common Stock	09/14/2007	S	2,776	D	\$ 22.4	108,598	D
Common Stock	09/14/2007	S	996	D	\$ 22.41	107,602	D
Common Stock	09/14/2007	S	1,628	D	\$ 22.42	105,974	D
Common Stock	09/14/2007	S	1,100	D	\$ 22.43	104,874	D
Common Stock	09/14/2007	S	3,500	D	\$ 22.44	101,374	D
Common Stock	09/14/2007	S	300	D	\$ 22.445	101,074	D
Common Stock	09/14/2007	S	3,852	D	\$ 22.45	97,222	D
Common Stock	09/14/2007	S	100	D	\$ 22.455	97,122	D
Common Stock	09/14/2007	S	3,600	D	\$ 22.46	93,522	D
Common Stock	09/14/2007	S	3,501	D	\$ 22.47	90,021	D
Common Stock	09/14/2007	S	4,597	D	\$ 22.48	85,424	D
Common Stock	09/14/2007	S	1,500	D	\$ 22.49	83,924	D
Common Stock	09/14/2007	S	5,000	D	\$ 22.5	78,924	D
Common Stock	09/14/2007	S	200	D	\$ 22.51	78,724	D
Common Stock	09/14/2007	S	500	D	\$ 22.52	78,224	D
Common Stock	09/14/2007	S	900	D	\$ 22.53	77,324	D
Common Stock	09/14/2007	S	3,500	D	\$ 22.54	73,824	D
	09/14/2007	S	3,700	D	\$ 22.55	70,124	D

Common Stock							
Common Stock	09/14/2007	S	1,000	D	\$ 22.56	69,124	D
Common Stock	09/14/2007	S	2,700	D	\$ 22.57	66,424	D
Common Stock	09/14/2007	S	4,000	D	\$ 22.58	62,424	D
Common Stock	09/14/2007	S	900	D	\$ 22.59	61,524	D
Common Stock	09/14/2007	S	5,693	D	\$ 22.6	55,831	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 6.13	09/14/2007		M	90,000	07/07/2005 <sup>(1)</sup>	01/06/2015	Common Stock	90,000

## Reporting Owners

### Reporting Owner Name / Address

### Relationships

Director 10% Owner Officer Other

BAFFI ROBERT  
C/O BIOMARIN PHARMACEUTICAL INC.  
105 DIGITAL DRIVE  
NOVATO, CA 94949

SVP, Technical Operations

## Signatures

/s/ G. Eric Davis,  
Attorney-in-Fact

09/18/2007

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Options vested 6/48ths on July 7, 2005 and 1/48th on the 7th of every month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.